Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.
The Latest Insights
PRESS RELEASE: Patients Rising Announces Advisory Board for Patient Access & Affordability Project
Leading experts in public policy, economics, and science will focus on the rare and chronic disease plight before lawmakers, regulators and insurers. WASHINGTON — Patients Rising, a non-profit organization advocating on behalf of patients with chronic and rare...
The Alzheimer’s Dilemma: Government and Private Payers Must Evolve or Die
By MacKay Jimeson In a proclamation last year, President Joe Biden said, “in the next 30 years, the number of Americans with Alzheimer’s is expected to reach nearly 14 million, straining families and our health care system. Fortunately, we are on the cusp of...
This Rare Disease Day we need to go beyond raising awareness and move towards tangible policy and regulatory action.
By MacKay Jimeson Too many patients and families are in crisis as we mark another Rare Disease Day. Policymakers are focused on debates on Accelerated Approval and drug pricing, while many patients are without treatment due to regulatory or insurance coverage...
PRESS RELEASE: Patient Group Releases Special Report on Biosimilar Market and Trends
New Publication: Patients’ Guide to Biologic Treatment Options
Recent advances in biologic medicines have revolutionized the treatment of many illnesses and conditions, from cancer to autoimmune diseases and many others. The FDA is also approving an increasing number of biologic treatments - including biosimilars - which means...
PRESS RELEASE: Patients Rising Releases New Rare Disease Drug Assessment Standards Aimed at Improving Health Equity
Press Contact: Sarah Shelsonsshelson@riesterpublicaffairs.com New framework for the evaluation of rare disease therapies prioritizes patient experiences, feedback, and needs WASHINGTON — Patients Rising, a non-profit organization that advocates on behalf of patients...
Healthcare That is Fit for Service
Veterans Have An Urgent Need for Better Healthcare Veterans are American heroes that deserve the highest level of respect, care and dignity that our nation can offer. Yet, Uncle Sam has fallen short on the promise to have the backs of the men and women who wore the...
ICER’s Latest: A draft evidence report on treatments for vasomotor symptoms of menopause
Op-Ed: Medicare’s cuts to home health are a step in the wrong direction
By Terry Wilcox
Co-Founder and CEO, Patients Rising
ICER’s Latest: A draft evidence report on gene therapies for Hemophilia A and B
On September 13, 2022 2021, ICER released a new draft evidence report, “Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in December...
Get Updates in Your Inbox
Sign Up. Stay Informed.